Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 26, 2015 8:41 PM ET


Company Overview of Braeburn Pharmaceuticals, Inc.

Company Overview

Braeburn Pharmaceuticals, Inc. develops and commercializes medical products. It develops Probuphine for the treatment of adult patients with opioid dependence. The company was founded in 2012 and is based in New York, New York.

New York, NY 

United States

Founded in 2012



Key Executives for Braeburn Pharmaceuticals, Inc.

Chief Executive Officer and President
Global Head of Quality Assurance and Quality Control
Age: 57
Executive Vice President of Clinical and Regulatory Affairs
Head of Commercialization for Apple Tree Partners and Partner of Apple Tree Partners
Age: 54
Vice President of Supply Chain
Age: 60
Compensation as of Fiscal Year 2014.

Braeburn Pharmaceuticals, Inc. Key Developments

Braeburn Pharmaceuticals, Inc. Enrolls First Patients in Late-Stage Clinical Study of Probuphine(R) for Opioid Dependence

Braeburn Pharmaceuticals, Inc. announced that the first patients have been enrolled in its Phase 3 clinical study of Probuphine(R), a subdermal implant for the maintenance treatment of opioid dependence. The trial is designed to address questions the agency posed in its complete response letter last year, after its review of the original New Drug Application (NDA). Completion of the Braeburn Phase 3 study is expected by the middle of 2015, to be followed by resubmission of the NDA later in the year. Fourteen sites are actively screening patients for randomization into the study, and five patients have already been enrolled. The clinical study is a randomized, double-blind, double-dummy design that is expected to enroll approximately 180 patients into two parallel treatment arms. The study population consists of clinically stable patients who are receiving maintenance treatment with an FDA-approved sublingual formulation containing buprenorphine at a daily dose of 8 mg or less. Patients are being randomized to receive either four Probuphine implants, or to continue daily sublingual buprenorphine therapy. To enable the double-blind design, those receiving Probuphine implants are required to take daily placebo sublingual pills, while those continuing on their stable dose of sublingual buprenorphine pills are required to be treated with four placebo implants. The patients are expected to be treated for six months, and the primary analysis will be a non-inferiority comparison of responders in the two arms.

Titan Pharmaceuticals Inc. Announces and Braeburn Pharmaceuticals Agreement in Principle on Path Forward for Probuphine Clinical Study with the U.S. Food and Drug Administration

Titan Pharmaceuticals Inc. announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.

Braeburn Pharmaceuticals, Inc. Appoints Frank E. Young as Executive Vice President, Clinical and Regulatory Affairs

Braeburn Pharmaceuticals, Inc. announced that former FDA Commissioner Frank E. Young, M.D., Ph.D., has joined the management team as Executive Vice President, Clinical and Regulatory Affairs. If approved, Braeburn's first product will be Probuphine(R), a buprenorphine implant for the maintenance treatment of opioid addiction, currently under review at the U.S. Food and Drug Administration (FDA). Braeburn has licensed rights from Titan Pharmaceuticals, Inc. to commercialize Probuphine in the U.S. and Canada. Dr. Young served as Commissioner of the U.S. Food and Drug Administration from 1984 to 1989 during the Reagan and Bush administrations.

Similar Private Companies By Industry

Company Name Region
VerCo Inc. United States
NanoMedex Pharmaceuticals, Inc. United States
Hill Dermaceuticals, Inc. United States
Rowell Laboratories, Inc. United States
Actavis LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Braeburn Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at